1211 Friday IPOs
BioCentury & Getty Images


AbCellera valuation tops $15B as 2020’s IPO class nears completion

COVID-19 program draws attention, nearly tripling value

The Canadian biotech’s COVID-19 program drew investors’ attention, almost tripling its value Friday.

Dec 11, 2020 | 11:43 PM GMT

As 2020’s record-setting run of biotech IPOs nears its end, Canadian mAb developer AbCellera rode enthusiasm for

Read the full 574 word article

How to gain access

Continue reading with a
two-week free trial.